Biokin Pharmaceutical (688506.SH): Yizekang New Indication Included in Priority Review Process

Zhito Finance APP News, Baili Tianheng (688506.SH) announced that recently, the company's independently developed globally first-in-class, new-concept, and the world's first and only approved EGFRHER3 bispecific antibody-drug conjugate (ADC), Yizekang (lunsekimig, BL-B01D1/iza-bren), has been included in the priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. According to publicly available information, Yizekang is also the world's first EGFRHER3 bispecific ADC to be included in the priority review variety list.